Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Considerations in the development of circulating tumor cell technology for clinical use.

Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth A, Hayes DF, Kapke G, Kumar P, Lee JSh, Liu MC, McCormack R, Mikulski S, Nagahara L, Pantel K, Pearson-White S, Punnoose EA, Roadcap LT, Schade AE, Scher HI, Sigman CC, Kelloff GJ.

J Transl Med. 2012 Jul 2;10:138. doi: 10.1186/1479-5876-10-138. Review.

2.

Biomarker development in the context of urologic cancers.

Kelloff GJ, Sigman CC, Scher HI.

Urol Oncol. 2015 Jun;33(6):295-301. doi: 10.1016/j.urolonc.2015.01.007. Epub 2015 Mar 5. Review.

3.

Circulating tumors cells as biomarkers: progress toward biomarker qualification.

Danila DC, Pantel K, Fleisher M, Scher HI.

Cancer J. 2011 Nov-Dec;17(6):438-50. doi: 10.1097/PPO.0b013e31823e69ac. Review.

4.

Rapid translation of circulating tumor cell biomarkers into clinical practice: technology development, clinical needs and regulatory requirements.

King JD, Casavant BP, Lang JM.

Lab Chip. 2014 Jan 7;14(1):24-31. doi: 10.1039/c3lc50741f. Epub 2013 Nov 5. Review.

PMID:
24190548
5.

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.

Tan DS, Thomas GV, Garrett MD, Banerji U, de Bono JS, Kaye SB, Workman P.

Cancer J. 2009 Sep-Oct;15(5):406-20. doi: 10.1097/PPO.0b013e3181bd0445. Review.

PMID:
19826361
6.

Cancer diagnostics: decision criteria for marker utilization in the clinic.

Taube SE, Jacobson JW, Lively TG.

Am J Pharmacogenomics. 2005;5(6):357-64. Review.

PMID:
16336001
7.

Circulating tumor cells as biomarkers in prostate cancer.

Danila DC, Fleisher M, Scher HI.

Clin Cancer Res. 2011 Jun 15;17(12):3903-12. doi: 10.1158/1078-0432.CCR-10-2650. Review.

8.

Circulating tumor cells: a multifunctional biomarker.

Yap TA, Lorente D, Omlin A, Olmos D, de Bono JS.

Clin Cancer Res. 2014 May 15;20(10):2553-68. doi: 10.1158/1078-0432.CCR-13-2664. Review.

9.

Challenges and opportunities in the use of CTCs for companion diagnostic development.

Punnoose EA, Lackner MR.

Recent Results Cancer Res. 2012;195:241-53. doi: 10.1007/978-3-642-28160-0_22. Review.

PMID:
22527511
10.

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial.

Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Vogelzang NJ, Thompson IM Jr, Cote RJ, Quinn DI.

Int J Cancer. 2015 Apr 15;136(8):1856-62. doi: 10.1002/ijc.29212. Epub 2014 Oct 8.

11.

Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.

Das A, Kunkel M, Joudeh J, Dicker DT, Scicchitano A, Allen JE, Sarwani N, Yang Z, Kaifi J, Zhu J, Liao J, El-Deiry WS.

Cancer Biol Ther. 2015;16(5):709-13. doi: 10.1080/15384047.2015.1030555.

12.

Detection of cancer cells on a chip.

Hao HC, Yao DJ.

Curr Top Med Chem. 2015;15(15):1543-50. Review.

PMID:
25877085
13.

Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

Tahara H, Sato M, Thurin M, Wang E, Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Wigginton JM, Ambs S, Akutsu Y, Chaussabel D, Doki Y, Eremin O, Fridman WH, Hirohashi Y, Imai K, Jacobson J, Jinushi M, Kanamoto A, Kashani-Sabet M, Kato K, Kawakami Y, Kirkwood JM, Kleen TO, Lehmann PV, Liotta L, Lotze MT, Maio M, Malyguine A, Masucci G, Matsubara H, Mayrand-Chung S, Nakamura K, Nishikawa H, Palucka AK, Petricoin EF, Pos Z, Ribas A, Rivoltini L, Sato N, Shiku H, Slingluff CL, Streicher H, Stroncek DF, Takeuchi H, Toyota M, Wada H, Wu X, Wulfkuhle J, Yaguchi T, Zeskind B, Zhao Y, Zocca MB, Marincola FM.

J Transl Med. 2009 Jun 17;7:45. doi: 10.1186/1479-5876-7-45.

14.

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.

Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BG, Hicks RJ, Hampton GM, Amler LC, Pirzkall A, Lackner MR.

Clin Cancer Res. 2012 Apr 15;18(8):2391-401. doi: 10.1158/1078-0432.CCR-11-3148. Epub 2012 Apr 5.

15.

Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors.

Goodman OB Jr, Fink LM, Symanowski JT, Wong B, Grobaski B, Pomerantz D, Ma Y, Ward DC, Vogelzang NJ.

Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1904-13. doi: 10.1158/1055-9965.EPI-08-1173.

16.

Circulating tumor cells: application as a biomarker for molecular characterization and predictor of survival in an all-comer solid tumor phase I clinical study.

Bao H, Burke PA, Huang J, Chen X, Brohawn PZ, Yao Y, Lechleider RJ, Sikorski RS, Buzoianu M, Zhang J, Shi X, Richman LK, Lavallee TM.

PLoS One. 2013 Aug 21;8(8):e58557. doi: 10.1371/journal.pone.0058557. eCollection 2013.

17.

Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients.

Mostert B, Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, van Galen A, Peeters DJ, Dirix LY, Seynaeve CM, Jager A, de Jongh FE, Hamberg P, Stouthard JM, Kehrer DF, Look MP, Smid M, Gratama JW, Foekens JA, Martens JW, Sleijfer S.

Ann Oncol. 2015 Mar;26(3):510-6. doi: 10.1093/annonc/mdu557. Epub 2014 Dec 3.

PMID:
25471333
18.

The use of circulating biomarkers in early clinical trials in patients with cancer.

D'Arcangelo M, Margetts J, Greystoke A.

Biomark Med. 2015;9(10):1011-23. doi: 10.2217/bmm.15.51. Epub 2015 Oct 6. Review.

PMID:
26441037
19.

Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.

Lieberman R, Nelson WG, Sakr WA, Meyskens FL Jr, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM.

Urology. 2001 Apr;57(4 Suppl 1):4-27.

PMID:
11295590
20.

Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.

Chang K, Kong YY, Dai B, Ye DW, Qu YY, Wang Y, Jia ZW, Li GX.

Oncotarget. 2015 Dec 8;6(39):41825-36. doi: 10.18632/oncotarget.6167.

Supplemental Content

Support Center